Immunovia
2.165 SEK +5.35%Be the first to follow this company
Immunovia is a biotechnology company. The company's research and development is focused on molecular diagnostics, where the business focuses on driving the development and change of current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests to be able to identify different types of pancreatic cancer at an early stage. The company was founded in 2007 and is headquartered in Lund.
Revenue
1.58M
EBIT %
-18,763.29 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
IMMNOV
Daily low / high price
2.06 / 2.34
SEK
Market cap
98.05M SEK
Turnover
1.67M SEK
Volume
761K
Financial calendar
Interim report
2024-04-29
Interim report
2024-08-22
Interim report
2024-11-14
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsbolaget Avanza Pension | 10.4 % | 10.4 % |
Carl Borrebaeck | 3.8 % | 3.8 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Immunovia AB: Immunovia utser Dr. Lisa Ford till klinisk laboratoriechef
Immunovia AB: Immunovia appoints Dr. Lisa Ford as Clinical Laboratory Director
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools